Details of Xenobiotics-DME Interaction (XEOTIC)

General Information of Drug-Metabolizing Enzyme (DME ID: DME0003)
DME Name	Cytochrome P450 1A2 (CYP1A2), Homo sapiens	DME Info
UniProt ID	CP1A2_HUMAN
EC Number	EC: 1.14.14.1 (Click to Show/Hide the Complete EC Tree) Oxidoreductase Oxygen paired donor oxidoreductase Flavin/flavoprotein donor oxidoreductase EC: 1.14.14.1
Lineage	Species: Homo sapiens (Click to Show/Hide the Complete Species Lineage) Kingdom: Metazoa Phylum: Chordata Class: Mammalia Order: Primates Family: Hominidae Genus: Homo Species: Homo sapiens
Interactome

Interactions between Xenobiotics and DME (XEOTIC)
Fungicide(s), Herbicide(s) or Insecticide(s)
Fungicide		Click to Show/Hide the Full List of Xenobiotics: 5 Xenobiotics
Azoxystrobin		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00938 XEOTIC Info		Gene Form	Protein
Classification	Fungicide
DME Modulation	Azoxystrobin induces the drug-metabolizing activity of DME CYP1A2				[1]
Cyproconazole		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00942 XEOTIC Info		Gene Form	mRNA
Classification	Fungicide
DME Modulation	Cyproconazole up-regulates the expression of DME CYP1A2				[2]
Prochloraz		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00955 XEOTIC Info		Gene Form	mRNA
Classification	Fungicide
DME Modulation	Prochloraz up-regulates the expression of DME CYP1A2				[3]
Propiconazole		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00956 XEOTIC Info		Gene Form	mRNA
Classification	Fungicide
DME Modulation	Propiconazole up-regulates the expression of DME CYP1A2				[4]
Tebuconazole		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00957 XEOTIC Info		Gene Form	Protein
Classification	Fungicide
DME Modulation	Tebuconazole induces the drug-metabolizing activity of DME CYP1A2				[5]
Herbicide		Click to Show/Hide the Full List of Xenobiotics: 4 Xenobiotics
Atrazine		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00969 XEOTIC Info		Gene Form	Protein
Classification	Herbicide
DME Modulation	Atrazine induces the drug-metabolizing activity of DME CYP1A2				[4]
Diuron		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00973 XEOTIC Info		Gene Form	Protein
Classification	Herbicide
DME Modulation	Diuron induces the drug-metabolizing activity of DME CYP1A2				[1]
Isoproturon		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00975 XEOTIC Info		Gene Form	Protein
Classification	Herbicide
DME Modulation	Isoproturon induces the drug-metabolizing activity of DME CYP1A2				[4]
Metolachlor		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00976 XEOTIC Info		Gene Form	mRNA
Classification	Herbicide
DME Modulation	Metolachlor up-regulates the expression of DME CYP1A2				[6]
Pesticide/Insecticide		Click to Show/Hide the Full List of Xenobiotics: 11 Xenobiotics
1-chloronaphthalene		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01035 XEOTIC Info		Gene Form	Protein
Classification	Pesticide/Insecticide
DME Modulation	1-chloronaphthalene inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 50 microM)				[7]
Cyhalothrin		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO01600 XEOTIC Info		Gene Form	Protein
Classification	Pesticide/Insecticide
DME Modulation	Cyhalothrin induces the drug-metabolizing activity of DME CYP1A2				[4]
Dicrotophos		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO01050 XEOTIC Info		Gene Form	mRNA
Classification	Pesticide/Insecticide
DME Modulation	Dicrotophos up-regulates the expression of DME CYP1A2				[8]
Fenitrothion		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01052 XEOTIC Info		Gene Form	Protein
Classification	Pesticide/Insecticide
DME Modulation	Fenitrothion inhibits the drug-metabolizing activity of DME CYP1A2				[9], [10]
Fenvalerate		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO01053 XEOTIC Info		Gene Form	Protein
Classification	Pesticide/Insecticide
DME Modulation	Fenvalerate induces the drug-metabolizing activity of DME CYP1A2				[4]
Fonofos		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01054 XEOTIC Info		Gene Form	Protein
Classification	Pesticide/Insecticide
DME Modulation	Fonof DMEos inhibits the drug-metabolizing activity of DME CYP1A2				[11]
Isomalathion		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01058 XEOTIC Info		Gene Form	mRNA
Classification	Pesticide/Insecticide
DME Modulation	Isomalathion inhibits the expression of DME CYP1A2				[12]
Myristicin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01075 XEOTIC Info		Gene Form	mRNA
Classification	Pesticide/Insecticide
DME Modulation	Myristicin inhibits the expression of DME CYP1A2				[13]
Parathion		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO01064 XEOTIC Info		Gene Form	mRNA
Classification	Pesticide/Insecticide
DME Modulation	Parathion up-regulates the expression of DME CYP1A2				[14]
Piperonyl butoxide		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00889 XEOTIC Info		Gene Form	Protein
Classification	Pesticide/Insecticide
DME Modulation	Piperonyl butoxide induces the drug-metabolizing activity of DME CYP1A2				[15]
Profenofos		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01068 XEOTIC Info		Gene Form	mRNA
Classification	Pesticide/Insecticide
DME Modulation	Profenofos inhibits the expression of DME CYP1A2				[16]
Health or Environmental Toxicant(s)
Acute Toxic Substance		Click to Show/Hide the Full List of Xenobiotics: 7 Xenobiotics
1,4-naphthoquinone		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO01089 XEOTIC Info		Gene Form	mRNA
Classification	Acute Toxic Substance
DME Modulation	1,4-naphthoquinone up-regulates the expression of DME CYP1A2				[17]
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO01119 XEOTIC Info		Gene Form	mRNA
Classification	Acute Toxic Substance
DME Modulation	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine up-regulates the expression of DME CYP1A2				[18]
Chlorpyrifos		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01248 XEOTIC Info		Gene Form	Protein
Classification	Acute Toxic Substance
DME Modulation	Chlorpyrifos inhibits the drug-metabolizing activity of DME CYP1A2				[10]
Kaempferol		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01353 XEOTIC Info		Gene Form	Protein
Classification	Acute Toxic Substance
DME Modulation	Kaempferol inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 0.716 microM)				[19]
Mercuric chloride		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01508 XEOTIC Info		Gene Form	mRNA
Classification	Acute Toxic Substance
DME Modulation	Mercuric chloride inhibits the expression of DME CYP1A2				[20]
Nickel chloride		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01397 XEOTIC Info		Gene Form	mRNA
Classification	Acute Toxic Substance
DME Modulation	Nickel chloride inhibits the expression of DME CYP1A2				[21], [22]
Ochratoxin A		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO01407 XEOTIC Info		Gene Form	Protein
Classification	Acute Toxic Substance
DME Modulation	Ochratoxin A induces the drug-metabolizing activity of DME CYP1A2				[23], [24]
Biotoxin		Click to Show/Hide the Full List of Xenobiotics: 2 Xenobiotics
Cylindrospermopsin		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00905 XEOTIC Info		Gene Form	mRNA
Classification	Cyanotoxin
DME Modulation	Cylindrospermopsin up-regulates the expression of DME CYP1A2				[25]
8-prenylnaringenin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01179 XEOTIC Info		Gene Form	Protein
Classification	Cytotoxin
DME Modulation	8-prenylnaringenin inhibits the drug-metabolizing activity of DME CYP1A2				[26]
Carcinogen		Click to Show/Hide the Full List of Xenobiotics: 6 Xenobiotics
2-amino-3-methylimidazo(4,5-f)quinoline		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00895 XEOTIC Info		Gene Form	mRNA
Classification	Carcinogen
DME Modulation	2-amino-3-methylimidazo(4,5-f)quinoline up-regulates the expression of DME CYP1A2				[27]
Benz(a)anthracenes		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00897 XEOTIC Info		Gene Form	mRNA
Classification	Carcinogen
DME Modulation	Benz(a)anthracenes up-regulates the expression of DME CYP1A2				[28]
Benzo(a)pyrene		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00898 XEOTIC Info		Gene Form	Protein
Classification	Carcinogen
DME Modulation	Benzo(a)pyrene inhibits the drug-metabolizing activity of DME CYP1A2 in Cellosaurus cell line BTI-Tn-5B1-4 (IC50 = 0.04 microM)				[29]
Methylcholanthrene		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00899 XEOTIC Info		Gene Form	Protein
Classification	Carcinogen
DME Modulation	Methylcholanthrene induces the drug-metabolizing activity of DME CYP1A2				[30]
Polychlorinated biphenyls		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00776 XEOTIC Info		Gene Form	Protein
Classification	Carcinogen
DME Modulation	Polychlorinated biphenyls induces the drug-metabolizing activity of DME CYP1A2				[31], [32]
Aflatoxin B1		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00806 XEOTIC Info		Gene Form	mRNA
Classification	Carcinogen-mycotoxin
DME Modulation	Aflatoxin B1 inhibits the expression of DME CYP1A2				[33]
Environmental Pollutant		Click to Show/Hide the Full List of Xenobiotics: 7 Xenobiotics
2,6-dimethylnaphthalene		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00988 XEOTIC Info		Gene Form	Protein
Classification	Environmental Pollutant
DME Modulation	2,6-dimethylnaphthalene inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 52 microM)				[7]
2-naphthol		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00990 XEOTIC Info		Gene Form	Protein
Classification	Environmental Pollutant
DME Modulation	2-naphthol inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 17 microM)				[7]
3,4',5-trimethoxystilbene		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO01135 XEOTIC Info		Gene Form	Protein
Classification	Environmental Pollutant
DME Modulation	3,4',5-trimethoxystilbene induces the drug-metabolizing activity of DME CYP1A2				[34]
6-nitrochrysene		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00794 XEOTIC Info		Gene Form	mRNA
Classification	Environmental Pollutant
DME Modulation	6-nitrochrysene up-regulates the expression of DME CYP1A2				[28]
Diazinon		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO01274 XEOTIC Info		Gene Form	Protein
Classification	Environmental Pollutant
DME Modulation	Diazinon induces the drug-metabolizing activity of DME CYP1A2				[1]
NCX-4040		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01394 XEOTIC Info		Gene Form	Protein
Classification	Environmental Pollutant
DME Modulation	NCX-4040 inhibits the drug-metabolizing activity of DME CYP1A2				[35]
Polychlorinated dibenzodioxin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00917 XEOTIC Info		Gene Form	Protein
Classification	Environmental Pollutant
DME Modulation	Polychlorinated dibenzodioxin inhibits the drug-metabolizing activity of DME CYP1A2				[36]
Health Hazard/Toxicant		Click to Show/Hide the Full List of Xenobiotics: 5 Xenobiotics
6-nitrobenzo(a)pyrene		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00913 XEOTIC Info		Gene Form	mRNA
Classification	Health and Environmental Toxicant
DME Modulation	6-nitrobenzo(a)pyrene up-regulates the expression of DME CYP1A2				[28]
Lead nitrate		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01507 XEOTIC Info		Gene Form	Protein
Classification	Health and Environmental Toxicant
DME Modulation	Lead nitrate inhibits the drug-metabolizing activity of DME CYP1A2				[29]
2-methylindole		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00989 XEOTIC Info		Gene Form	Protein
Classification	Health Hazard
DME Modulation	2-methylindole induces the drug-metabolizing activity of DME CYP1A2				[37]
Alpha-linolenic acid		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00873 XEOTIC Info		Gene Form	Protein
Classification	Health Hazard
DME Modulation	Alpha-linolenic acid inhibits the drug-metabolizing activity of DME CYP1A2				[38]
Indan		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01012 XEOTIC Info		Gene Form	Protein
Classification	Health Hazard
DME Modulation	Indan inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 550 microM)				[7]
Natural Product(s), Extract(s) or Medicine(s)
Natural Mixture		Click to Show/Hide the Full List of Xenobiotics: 4 Xenobiotics
Coal tar		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00755 XEOTIC Info		Gene Form	mRNA
Classification	Natural Mixture
DME Modulation	Coal tar up-regulates the expression of DME CYP1A2				[39]
Cyclodextrins		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00857 XEOTIC Info		Gene Form	Protein
Classification	Natural Mixture
DME Modulation	Cyclodextrins inhibits the drug-metabolizing activity of DME CYP1A2				[40]
Dust		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO01284 XEOTIC Info		Gene Form	mRNA
Classification	Natural Mixture
DME Modulation	Dust up-regulates the expression of DME CYP1A2				[41]
Tobacco smoke pollution		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00821 XEOTIC Info		Gene Form	Protein
Classification	Natural Mixture
DME Modulation	Tobacco smoke pollution up-regulates the expression of DME CYP1A2 and leads to increasing the drug-metabolizing activity of this enzyme				[42]
Natural Product		Click to Show/Hide the Full List of Xenobiotics: 42 Xenobiotics
1-methylxanthine		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01104 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	1-methylxanthine inhibits the drug-metabolizing activity of DME CYP1A2				[43]
15,16-dihydrotanshinone I		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO01517 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	15,16-dihydrotanshinone I induces the drug-metabolizing activity of DME CYP1A2				[44]
5-hydroxyflavone		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01161 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	5-hydroxyflavone inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 0.31 microM)				[45]
5-methyltryptamine		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01518 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	5-methyltryptamine inhibits the drug-metabolizing activity of DME CYP1A2				[46]
6-bromoindirubin-3'-oxime		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO01168 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	6-bromoindirubin-3'-oxime up-regulates the expression of DME CYP1A2 and leads to increasing the drug-metabolizing activity of this enzyme				[47]
7-hydroxyflavone		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01176 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	7-hydroxyflavone inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 0.24 microM)				[48]
Acacetin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01184 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Acacetin inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 0.08 microM)				[49]
Alizarin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00993 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Alizarin inhibits the drug-metabolizing activity of DME CYP1A2				[50]
Allocryptopine		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO01519 XEOTIC Info		Gene Form	mRNA
Classification	Natural Product
DME Modulation	Allocryptopine up-regulates the expression of DME CYP1A2				[51]
Aloe-emodin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01191 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Aloe-emodin inhibits the drug-metabolizing activity of DME CYP1A2				[52]
Alpha-naphthoflavone		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01192 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Alpha-naphthof DMElavone inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 0.0038 microM)				[53]
Apigenin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01203 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Apigenin inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 0.795 microM)				[19]
Artemisin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00863 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Artemisin inhibits the drug-metabolizing activity of DME CYP1A2				[54]
Baicalein		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01212 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Baicalein inhibits the drug-metabolizing activity of DME CYP1A2				[55], [56]
BDE-99		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00925 XEOTIC Info		Gene Form	mRNA
Classification	Natural Product
DME Modulation	BDE-99 up-regulates the expression of DME CYP1A2				[57]
Biochanin A		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01222 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Biochanin A inhibits the drug-metabolizing activity of DME CYP1A2				[58]
Chrysin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00878 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Chrysin inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 0.054 microM)				[48]
Chrysophanic acid		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01528 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Chrysophanic acid inhibits the drug-metabolizing activity of DME CYP1A2				[52]
Cryptotanshinone		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO01534 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Cryptotanshinone induces the drug-metabolizing activity of DME CYP1A2				[44]
Dihydrocapsaicin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00802 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Dihydrocapsaicin inhibits the drug-metabolizing activity of DME CYP1A2				[59]
Diosmetin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01281 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Diosmetin inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 2.437 microM)				[19]
Flavone		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01304 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Flavone inhibits the drug-metabolizing activity of DME CYP1A2				[55]
Galangin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01308 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Galangin inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 0.04 microM)				[19]
Gamma-valerolactone		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01544 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Gamma-valerolactone inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 15000 microM)				[7]
Germacrone		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01313 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Germacrone inhibits the drug-metabolizing activity of DME CYP1A2				[60]
Hesperetin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00856 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Hesperetin inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 34.647 microM)				[19]
Inermin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01345 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Inermin inhibits the drug-metabolizing activity of DME CYP1A2				[56]
Isoxanthohumol		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00811 XEOTIC Info		Gene Form	mRNA
Classification	Natural Product
DME Modulation	Isoxanthohumol up-regulates the expression of DME CYP1A2				[61]
Mangiferin		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO01370 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Mangiferin up-regulates the expression of DME CYP1A2 and leads to increasing the drug-metabolizing activity of this enzyme				[62]
Mitragynine		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO01564 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Mitragynine induces the drug-metabolizing activity of DME CYP1A2				[63]
Naringin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01391 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Naringin inhibits the drug-metabolizing activity of DME CYP1A2				[64]
Olivacine		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO01415 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Olivacine induces the drug-metabolizing activity of DME CYP1A2				[65]
Pelargonidin		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO01424 XEOTIC Info		Gene Form	mRNA
Classification	Natural Product
DME Modulation	Pelargonidin up-regulates the expression of DME CYP1A2				[66]
Physcione		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01572 XEOTIC Info		Gene Form	mRNA
Classification	Natural Product
DME Modulation	Physcione inhibits the expression of DME CYP1A2				[20]
Polycyclic aromatic hydrocarbon		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00827 XEOTIC Info		Gene Form	mRNA
Classification	Natural Product
DME Modulation	Polycyclic aromatic hydrocarbon up-regulates the expression of DME CYP1A2				[67]
Protopine		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO01581 XEOTIC Info		Gene Form	mRNA
Classification	Natural Product
DME Modulation	Protopine up-regulates the expression of DME CYP1A2				[68]
Puag-haad		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01442 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Puag-haad inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 150 microM)				[69]
Purpurin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01443 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Purpurin inhibits the drug-metabolizing activity of DME CYP1A2				[70]
Rutecarpine		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01462 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Rutecarpine inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 0.022 microM)				[71]
Safrole		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01583 XEOTIC Info		Gene Form	Protein
Classification	Natural Product
DME Modulation	Safrole inhibits the drug-metabolizing activity of DME CYP1A2 in Cellosaurus cell line BTI-Tn-5B1-4 (IC50 = 10 microM)				[72]
Steviol		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00810 XEOTIC Info		Gene Form	mRNA
Classification	Natural Product
DME Modulation	Steviol up-regulates the expression of DME CYP1A2				[73], [74]
Tamarixetin		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO01479 XEOTIC Info		Gene Form	mRNA
Classification	Natural Product
DME Modulation	Tamarixetin up-regulates the expression of DME CYP1A2				[75]
Plant Extract		Click to Show/Hide the Full List of Xenobiotics: 2 Xenobiotics
Ginkgo biloba extract		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01314 XEOTIC Info		Gene Form	Protein
Classification	Plant Extract
DME Modulation	Ginkgo biloba extract inhibits the drug-metabolizing activity of DME CYP1A2				[76]
Plant extracts		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01574 XEOTIC Info		Gene Form	Protein
Classification	Plant Extract
DME Modulation	Plant extracts inhibits the drug-metabolizing activity of DME CYP1A2				[77]
Pharmaceutical Agent(s)
Approved/Marketed Drug		Click to Show/Hide the Full List of Xenobiotics: 72 Xenobiotics
Albendazole		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00003 XEOTIC Info		Gene Form	mRNA
Classification	Drug Approved by US FDA
DME Modulation	Albendazole up-regulates the expression of DME CYP1A2				[78]
Amiodarone hydrochloride		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00277 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Amiodarone hydrochloride inhibits the drug-metabolizing activity of DME CYP1A2				[46], [79]
Atovaquone		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00143 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Atovaquone induces the drug-metabolizing activity of DME CYP1A2				[70]
Azacitidine		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00102 XEOTIC Info		Gene Form	mRNA
Classification	Drug Approved by US FDA
DME Modulation	Azacitidine up-regulates the expression of DME CYP1A2				[80]
Caffeine		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00218 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Caffeine inhibits the drug-metabolizing activity of DME CYP1A2				[43], [81]
Cannabidiol		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00173 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Cannabidiol inhibits the drug-metabolizing activity of DME CYP1A2				[82]
Capsaicin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00178 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Capsaicin inhibits the drug-metabolizing activity of DME CYP1A2 in Cellosaurus cell line BTI-Tn-5B1-4 (IC50 = 3 microM)				[59]
Carbamazepine		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00011 XEOTIC Info		Gene Form	mRNA
Classification	Drug Approved by US FDA
DME Modulation	Carbamazepine up-regulates the expression of DME CYP1A2				[83]
Celecoxib		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00013 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Celecoxib inhibits the drug-metabolizing activity of DME CYP1A2				[84]
Cimetidine		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00015 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Cimetidine inhibits the drug-metabolizing activity of DME CYP1A2				[85]
Ciprofloxacin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00349 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Ciprof DMEloxacin inhibits the drug-metabolizing activity of DME CYP1A2				[84]
Copper sulfate		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00117 XEOTIC Info		Gene Form	mRNA
Classification	Drug Approved by US FDA
DME Modulation	Copper sulfate inhibits the expression of DME CYP1A2				[86]
Decitabine		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00168 XEOTIC Info		Gene Form	mRNA
Classification	Drug Approved by US FDA
DME Modulation	Decitabine up-regulates the expression of DME CYP1A2				[87], [88]
Dehydroepiandrosterone		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00393 XEOTIC Info		Gene Form	mRNA
Classification	Drug Approved by US FDA
DME Modulation	Dehydroepiandrosterone inhibits the expression of DME CYP1A2				[89]
Desogestrel		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00432 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Desogestrel inhibits the drug-metabolizing activity of DME CYP1A2				[84]
Dexamethasone		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00088 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Dexamethasone inhibits the drug-metabolizing activity of DME CYP1A2				[90]
Diclofenac		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00352 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Diclof DMEenac inhibits the drug-metabolizing activity of DME CYP1A2				[91]
Dimethyl sulfoxide		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00001 XEOTIC Info		Gene Form	mRNA
Classification	Drug Approved by US FDA
DME Modulation	Dimethyl sulfoxide up-regulates the expression of DME CYP1A2				[92]
Enoxacin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00030 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Enoxacin inhibits the drug-metabolizing activity of DME CYP1A2				[93]
Estradiol		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00090 XEOTIC Info		Gene Form	mRNA
Classification	Drug Approved by US FDA
DME Modulation	Estradiol inhibits the expression of DME CYP1A2				[88]
Ethambutol		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00357 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Ethambutol inhibits the drug-metabolizing activity of DME CYP1A2				[94]
Ethinyl estradiol		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00267 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Ethinyl estradiol inhibits the drug-metabolizing activity of DME CYP1A2				[84]
Etodolac		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00034 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Etodolac inhibits the drug-metabolizing activity of DME CYP1A2				[84]
Felodipine		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00245 XEOTIC Info		Gene Form	mRNA
Classification	Drug Approved by US FDA
DME Modulation	Felodipine up-regulates the expression of DME CYP1A2				[95]
Fluvoxamine		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00360 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Fluvoxamine inhibits the drug-metabolizing activity of DME CYP1A2				[46]
Gemfibrozil		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00042 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Gemfibrozil inhibits the drug-metabolizing activity of DME CYP1A2				[46]
Ibuprofen		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00248 XEOTIC Info		Gene Form	mRNA
Classification	Drug Approved by US FDA
DME Modulation	Ibuprofen inhibits the expression of DME CYP1A2				[96]
Ifosfamide		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00046 XEOTIC Info		Gene Form	mRNA
Classification	Drug Approved by US FDA
DME Modulation	Ifosfamide up-regulates the expression of DME CYP1A2				[96]
Isradipine		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00049 XEOTIC Info		Gene Form	mRNA
Classification	Drug Approved by US FDA
DME Modulation	Isradipine up-regulates the expression of DME CYP1A2				[95]
Ketoconazole		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00251 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Ketoconazole inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 26 microM)				[97]
Lansoprazole		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00052 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Lansoprazole induces the drug-metabolizing activity of DME CYP1A2				[98], [99]
Leflunomide		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00053 XEOTIC Info		Gene Form	mRNA
Classification	Drug Approved by US FDA
DME Modulation	Leflunomide up-regulates the expression of DME CYP1A2				[100]
Malathion		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00056 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Malathion induces the drug-metabolizing activity of DME CYP1A2				[101]
Mefenamic acid		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00059 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Mefenamic acid inhibits the drug-metabolizing activity of DME CYP1A2				[102]
Methoxsalen		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00062 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Methoxsalen inhibits the drug-metabolizing activity of DME CYP1A2 in Cellosaurus cell line BTI-Tn-5B1-4 (IC50 = 0.04 microM)				[103]
Nicardipine hydrochloride		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00311 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Nicardipine hydrochloride inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 13.3 microM)				[104]
Niclosamide		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00405 XEOTIC Info		Gene Form	mRNA
Classification	Drug Approved by US FDA
DME Modulation	Niclosamide inhibits the expression of DME CYP1A2				[21], [22]
Nicotine polacrilex		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00312 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Nicotine polacrilex inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 4100 microM)				[7]
Nifedipine		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00066 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Nifedipine inhibits the drug-metabolizing activity of DME CYP1A2 in Cellosaurus cell line BTI-Tn-5B1-4 (IC50 = 0.3 microM)				[105]
Nisoldipine		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00067 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Nisoldipine inhibits the drug-metabolizing activity of DME CYP1A2 in Cellosaurus cell line BTI-Tn-5B1-4 (IC50 = 1 microM)				[105]
Omeprazole		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00069 XEOTIC Info		Gene Form	mRNA
Classification	Drug Approved by US FDA
DME Modulation	Omeprazole inhibits the expression of DME CYP1A2				[106]
Orphenadrine hydrochloride		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00314 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Orphenadrine hydrochloride inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 > 30 microM)				[97]
Permethrin		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00123 XEOTIC Info		Gene Form	mRNA
Classification	Drug Approved by US FDA
DME Modulation	Permethrin up-regulates the expression of DME CYP1A2				[107]
Phenobarbital		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00410 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Phenobarbital inhibits the drug-metabolizing activity of DME CYP1A2				[108]
Primaquine		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00258 XEOTIC Info		Gene Form	mRNA
Classification	Drug Approved by US FDA
DME Modulation	Primaquine up-regulates the expression of DME CYP1A2				[109]
Quinidine		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00225 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Quinidine inhibits the drug-metabolizing activity of DME CYP1A2				[110]
Quinine		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00180 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Quinine induces the drug-metabolizing activity of DME CYP1A2				[111]
Rifampin		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00223 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Rifampin induces the drug-metabolizing activity of DME CYP1A2				[112], [113]
Ritonavir		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00160 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Ritonavir induces the drug-metabolizing activity of DME CYP1A2				[114]
Rosiglitazone		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00380 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Rosiglitazone induces the drug-metabolizing activity of DME CYP1A2				[115]
Semaxanib		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00409 XEOTIC Info		Gene Form	mRNA
Classification	Drug Approved by US FDA
DME Modulation	Semaxanib up-regulates the expression of DME CYP1A2				[116]
Sulindac		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00177 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Sulindac induces the drug-metabolizing activity of DME CYP1A2				[117]
Tamoxifen		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00383 XEOTIC Info		Gene Form	mRNA
Classification	Drug Approved by US FDA
DME Modulation	Tamoxifen up-regulates the expression of DME CYP1A2				[118]
Thiabendazole		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00084 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Thiabendazole inhibits the drug-metabolizing activity of DME CYP1A2 in Cellosaurus cell line BTI-Tn-5B1-4 (IC50 = 0.8 microM)				[70], [54]
Ticlopidine hydrochloride		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00331 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Ticlopidine hydrochloride inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 8.59 microM)				[104]
Tretinoin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00253 XEOTIC Info		Gene Form	mRNA
Classification	Drug Approved by US FDA
DME Modulation	Tretinoin inhibits the expression of DME CYP1A2				[119], [120]
Trimethoprim		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00263 XEOTIC Info		Gene Form	mRNA
Classification	Drug Approved by US FDA
DME Modulation	Trimethoprim inhibits the expression of DME CYP1A2				[121], [20]
Zileuton		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00131 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Zileuton inhibits the drug-metabolizing activity of DME CYP1A2 (Ki = 117 microM)				[122]
Zoledronic acid		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00140 XEOTIC Info		Gene Form	Protein
Classification	Drug Approved by US FDA
DME Modulation	Zoledronic acid induces the drug-metabolizing activity of DME CYP1A2				[123]
Amodiaquine		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00489 XEOTIC Info		Gene Form	Protein
Classification	Drug Marketed but not Approved by US FDA
DME Modulation	Amodiaquine inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 41 microM)				[104]
Artemisinine		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00449 XEOTIC Info		Gene Form	Protein
Classification	Drug Marketed but not Approved by US FDA
DME Modulation	Artemisinine inhibits the drug-metabolizing activity of DME CYP1A2 in Cellosaurus cell line BTI-Tn-5B1-4 (IC50 = 2 microM)				[70]
Benidipine		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00438 XEOTIC Info		Gene Form	mRNA
Classification	Drug Marketed but not Approved by US FDA
DME Modulation	Benidipine up-regulates the expression of DME CYP1A2				[95]
Clodronic acid		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00465 XEOTIC Info		Gene Form	mRNA
Classification	Drug Marketed but not Approved by US FDA
DME Modulation	Clodronic acid up-regulates the expression of DME CYP1A2				[96]
Dihydroartemisinin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00454 XEOTIC Info		Gene Form	Protein
Classification	Drug Marketed but not Approved by US FDA
DME Modulation	Dihydroartemisinin inhibits the drug-metabolizing activity of DME CYP1A2				[70]
Etoricoxib		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00497 XEOTIC Info		Gene Form	Protein
Classification	Drug Marketed but not Approved by US FDA
DME Modulation	Etoricoxib inhibits the drug-metabolizing activity of DME CYP1A2				[84]
Formononetin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01306 XEOTIC Info		Gene Form	Protein
Classification	Drug Marketed but not Approved by US FDA
DME Modulation	Formononetin inhibits the drug-metabolizing activity of DME CYP1A2				[58]
Linoleic acid		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01367 XEOTIC Info		Gene Form	Protein
Classification	Drug Marketed but not Approved by US FDA
DME Modulation	Linoleic acid inhibits the drug-metabolizing activity of DME CYP1A2				[38]
Melatonin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00505 XEOTIC Info		Gene Form	Protein
Classification	Drug Marketed but not Approved by US FDA
DME Modulation	Melatonin inhibits the drug-metabolizing activity of DME CYP1A2 (Ki = 12 microM)				[124]
Methoxychlor		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00446 XEOTIC Info		Gene Form	mRNA
Classification	Drug Marketed but not Approved by US FDA
DME Modulation	Methoxychlor up-regulates the expression of DME CYP1A2				[125]
Stevioside		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00448 XEOTIC Info		Gene Form	Protein
Classification	Drug Marketed but not Approved by US FDA
DME Modulation	Stevioside induces the drug-metabolizing activity of DME CYP1A2				[126]
Suramin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00485 XEOTIC Info		Gene Form	Protein
Classification	Drug Marketed but not Approved by US FDA
DME Modulation	Suramin inhibits the drug-metabolizing activity of DME CYP1A2				[127]
Tanshinone		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00486 XEOTIC Info		Gene Form	mRNA
Classification	Drug Marketed but not Approved by US FDA
DME Modulation	Tanshinone up-regulates the expression of DME CYP1A2				[128]
Drug in Phase 3 Clinical Trial		Click to Show/Hide the Full List of Xenobiotics: 5 Xenobiotics
Curcumin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00683 XEOTIC Info		Gene Form	Protein
Classification	Highest Clinical Status: Phase 3
DME Modulation	Curcumin inhibits the drug-metabolizing activity of DME CYP1A2				[129]
Diethyltoluamide		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00582 XEOTIC Info		Gene Form	mRNA
Classification	Highest Clinical Status: Phase 3
DME Modulation	Diethyltoluamide up-regulates the expression of DME CYP1A2				[130], [131]
Oltipraz		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00605 XEOTIC Info		Gene Form	Protein
Classification	Highest Clinical Status: Phase 3
DME Modulation	Oltipraz inhibits the drug-metabolizing activity of DME CYP1A2 (Ki = 9 microM)				[122]
Resveratrol		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00568 XEOTIC Info		Gene Form	Protein
Classification	Highest Clinical Status: Phase 3
DME Modulation	Resveratrol inhibits the drug-metabolizing activity of DME CYP1A2 in Cellosaurus cell line BTI-Tn-5B1-4 (IC50 = 3 microM)				[132], [133]
Sulforafan		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01478 XEOTIC Info		Gene Form	Protein
Classification	Highest Clinical Status: Phase 3
DME Modulation	Sulforafan inhibits the drug-metabolizing activity of DME CYP1A2				[56]
Drug in Phase 2 Clinical Trial		Click to Show/Hide the Full List of Xenobiotics: 9 Xenobiotics
Butyric acid		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO01230 XEOTIC Info		Gene Form	mRNA
Classification	Highest Clinical Status: Phase 2/3
DME Modulation	Butyric acid up-regulates the expression of DME CYP1A2				[134]
Andrographolide		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00543 XEOTIC Info		Gene Form	mRNA
Classification	Highest Clinical Status: Phase 2
DME Modulation	Andrographolide inhibits the expression of DME CYP1A2				[135]
Butylcyclohexane		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00595 XEOTIC Info		Gene Form	Protein
Classification	Highest Clinical Status: Phase 2
DME Modulation	Butylcyclohexane inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 55 microM)				[7]
Genistein		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00557 XEOTIC Info		Gene Form	Protein
Classification	Highest Clinical Status: Phase 2
DME Modulation	Genistein inhibits the drug-metabolizing activity of DME CYP1A2				[56]
Icaritin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00653 XEOTIC Info		Gene Form	Protein
Classification	Highest Clinical Status: Phase 2
DME Modulation	Icaritin inhibits the drug-metabolizing activity of DME CYP1A2				[56]
MeIQx		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00609 XEOTIC Info		Gene Form	Protein
Classification	Highest Clinical Status: Phase 2
DME Modulation	MeIQx induces the drug-metabolizing activity of DME CYP1A2				[136]
Phenethyl isothiocyanate		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00596 XEOTIC Info		Gene Form	Protein
Classification	Highest Clinical Status: Phase 2
DME Modulation	Phenethyl isothiocyanate induces the drug-metabolizing activity of DME CYP1A2				[108]
Pinocembrin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00618 XEOTIC Info		Gene Form	Protein
Classification	Highest Clinical Status: Phase 2
DME Modulation	Pinocembrin inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 1.491 microM)				[19]
Sulindac sulfide		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00656 XEOTIC Info		Gene Form	mRNA
Classification	Highest Clinical Status: Phase 2
DME Modulation	Sulindac sulfide up-regulates the expression of DME CYP1A2				[137]
Drug in Phase 1 Clinical Trial		Click to Show/Hide the Full List of Xenobiotics: 13 Xenobiotics
Tolfenamic acid		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00556 XEOTIC Info		Gene Form	mRNA
Classification	Highest Clinical Status: Phase 1/2
DME Modulation	Tolfenamic acid inhibits the expression of DME CYP1A2				[138]
Carbendazim		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00598 XEOTIC Info		Gene Form	Protein
Classification	Highest Clinical Status: Phase 1
DME Modulation	Carbendazim induces the drug-metabolizing activity of DME CYP1A2				[1]
Epsilon-viniferin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00646 XEOTIC Info		Gene Form	Protein
Classification	Highest Clinical Status: Phase 1
DME Modulation	Epsilon-viniferin inhibits the drug-metabolizing activity of DME CYP1A2				[139]
Flavanone		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00738 XEOTIC Info		Gene Form	Protein
Classification	Highest Clinical Status: Phase 1
DME Modulation	Flavanone inhibits the drug-metabolizing activity of DME CYP1A2				[55]
Licochalcone A		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01365 XEOTIC Info		Gene Form	Protein
Classification	Highest Clinical Status: Phase 1
DME Modulation	Licochalcone A inhibits the drug-metabolizing activity of DME CYP1A2				[140]
Luteolin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00537 XEOTIC Info		Gene Form	Protein
Classification	Highest Clinical Status: Phase 1
DME Modulation	Luteolin inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 3.37 microM)				[19]
Naringenin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00573 XEOTIC Info		Gene Form	Protein
Classification	Highest Clinical Status: Phase 1
DME Modulation	Naringenin inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 26.339 microM)				[19]
O(6)-benzylguanine		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01405 XEOTIC Info		Gene Form	Protein
Classification	Highest Clinical Status: Phase 1
DME Modulation	O(6)-benzylguanine inhibits the drug-metabolizing activity of DME CYP1A2				[141]
Quercetin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00538 XEOTIC Info		Gene Form	Protein
Classification	Highest Clinical Status: Phase 1
DME Modulation	Quercetin inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 1.55 microM)				[97]
Sodium arsenite		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00632 XEOTIC Info		Gene Form	Protein
Classification	Highest Clinical Status: Phase 1
DME Modulation	Sodium arsenite inhibits the drug-metabolizing activity of DME CYP1A2				[142]
SR-13668		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00668 XEOTIC Info		Gene Form	mRNA
Classification	Highest Clinical Status: Phase 1
DME Modulation	SR-13668 up-regulates the expression of DME CYP1A2				[143]
Trichostatin A		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO01492 XEOTIC Info		Gene Form	mRNA
Classification	Highest Clinical Status: Phase 1
DME Modulation	Trichostatin A up-regulates the expression of DME CYP1A2				[144]
Xanthohumol		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00636 XEOTIC Info		Gene Form	Protein
Classification	Highest Clinical Status: Phase 1
DME Modulation	Xanthohumol induces the drug-metabolizing activity of DME CYP1A2				[145]
Preclinical/Patented Drug		Click to Show/Hide the Full List of Xenobiotics: 13 Xenobiotics
1-aminobenzotriazole		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01099 XEOTIC Info		Gene Form	Protein
Classification	Drug in Preclinical Study
DME Modulation	1-aminobenzotriazole inhibits the drug-metabolizing activity of DME CYP1A2				[146]
Baicalin		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00702 XEOTIC Info		Gene Form	Protein
Classification	Drug in Preclinical Study
DME Modulation	Baicalin induces the drug-metabolizing activity of DME CYP1A2				[147]
Emodin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00692 XEOTIC Info		Gene Form	Protein
Classification	Drug in Preclinical Study
DME Modulation	Emodin inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 3.73 microM)				[124]
Isoliquiritigenin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00710 XEOTIC Info		Gene Form	Protein
Classification	Drug in Preclinical Study
DME Modulation	Isoliquiritigenin inhibits the drug-metabolizing activity of DME CYP1A2				[56]
LS-131849		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00714 XEOTIC Info		Gene Form	Protein
Classification	Drug in Preclinical Study
DME Modulation	LS-131849 inhibits the drug-metabolizing activity of DME CYP1A2				[148]
Myricetin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01384 XEOTIC Info		Gene Form	Protein
Classification	Drug in Preclinical Study
DME Modulation	Myricetin inhibits the drug-metabolizing activity of DME CYP1A2				[149]
Oleic acid		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01412 XEOTIC Info		Gene Form	mRNA
Classification	Drug in Preclinical Study
DME Modulation	Oleic acid inhibits the expression of DME CYP1A2				[150]
Proadifen		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01438 XEOTIC Info		Gene Form	mRNA
Classification	Drug in Preclinical Study
DME Modulation	Proadifen inhibits the expression of DME CYP1A2				[109]
Tcpobop		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO01088 XEOTIC Info		Gene Form	mRNA
Classification	Drug in Preclinical Study
DME Modulation	Tcpobop up-regulates the expression of DME CYP1A2				[151]
Chir-99021		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00736 XEOTIC Info		Gene Form	mRNA
Classification	Patented Pharmaceutical Agent
DME Modulation	Chir-99021 up-regulates the expression of DME CYP1A2				[47]
Ferulic acid		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00730 XEOTIC Info		Gene Form	Protein
Classification	Patented Pharmaceutical Agent
DME Modulation	Ferulic acid inhibits the drug-metabolizing activity of DME CYP1A2				[129]
GW-3965		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO01325 XEOTIC Info		Gene Form	mRNA
Classification	Patented Pharmaceutical Agent
DME Modulation	GW-3965 up-regulates the expression of DME CYP1A2				[152]
Okanin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00733 XEOTIC Info		Gene Form	mRNA
Classification	Patented Pharmaceutical Agent
DME Modulation	Okanin inhibits the expression of DME CYP1A2				[150]
Drug Marketed but Withdrawn from Market		Click to Show/Hide the Full List of Xenobiotics: 1 Xenobiotics
Cotinine		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00532 XEOTIC Info		Gene Form	Protein
Classification	Drug Marketed but Withdrawn from Market
DME Modulation	Cotinine inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 5400 microM)				[7]
Investigative Agent		Click to Show/Hide the Full List of Xenobiotics: 19 Xenobiotics
1-methyl-3-isobutylxanthine		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01102 XEOTIC Info		Gene Form	Protein
Classification	Investigative Agent
DME Modulation	1-methyl-3-isobutylxanthine inhibits the drug-metabolizing activity of DME CYP1A2				[43]
5-fluorotryptamine		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01159 XEOTIC Info		Gene Form	Protein
Classification	Investigative Agent
DME Modulation	5-fluorotryptamine inhibits the drug-metabolizing activity of DME CYP1A2				[46]
6,7-dihydroxyflavone		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01167 XEOTIC Info		Gene Form	Protein
Classification	Investigative Agent
DME Modulation	6,7-dihydroxyflavone inhibits the drug-metabolizing activity of DME CYP1A2				[55]
6-methyl-2-(phenylethynyl)pyridine		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01169 XEOTIC Info		Gene Form	Protein
Classification	Investigative Agent
DME Modulation	6-methyl-2-(phenylethynyl)pyridine inhibits the drug-metabolizing activity of DME CYP1A2				[148]
7-methyltryptamine		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01177 XEOTIC Info		Gene Form	Protein
Classification	Investigative Agent
DME Modulation	7-methyltryptamine inhibits the drug-metabolizing activity of DME CYP1A2				[46]
8-phenyltheophylline		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01178 XEOTIC Info		Gene Form	Protein
Classification	Investigative Agent
DME Modulation	8-phenyltheophylline inhibits the drug-metabolizing activity of DME CYP1A2				[43]
Arachidonic acid		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00876 XEOTIC Info		Gene Form	Protein
Classification	Investigative Agent
DME Modulation	Arachidonic acid inhibits the drug-metabolizing activity of DME CYP1A2				[38]
Avasimibe		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00804 XEOTIC Info		Gene Form	Protein
Classification	Investigative Agent
DME Modulation	Avasimibe inhibits the drug-metabolizing activity of DME CYP1A2				[153]
Benzyl selenocyanate		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01218 XEOTIC Info		Gene Form	Protein
Classification	Investigative Agent
DME Modulation	Benzyl selenocyanate inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 0.2 microM)				[124]
Beta-naphthoflavone		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01220 XEOTIC Info		Gene Form	Protein
Classification	Investigative Agent
DME Modulation	Beta-naphthof DMElavone inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 0.47 microM)				[45]
Cloflucarban		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO00909 XEOTIC Info		Gene Form	Protein
Classification	Investigative Agent
DME Modulation	Cloflucarban induces the drug-metabolizing activity of DME CYP1A2				[1]
DY-9760e		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01130 XEOTIC Info		Gene Form	Protein
Classification	Investigative Agent
DME Modulation	DY-9760e inhibits the drug-metabolizing activity of DME CYP1A2				[154]
Ethyl isopropylamiloride		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01293 XEOTIC Info		Gene Form	Protein
Classification	Investigative Agent
DME Modulation	Ethyl isopropylamiloride inhibits the drug-metabolizing activity of DME CYP1A2				[155]
Furafylline		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01307 XEOTIC Info		Gene Form	Protein
Classification	Investigative Agent
DME Modulation	Furafylline inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 0.3 microM)				[156]
Indacrinone		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01341 XEOTIC Info		Gene Form	Protein
Classification	Investigative Agent
DME Modulation	Indacrinone inhibits the drug-metabolizing activity of DME CYP1A2				[7]
MPC1304		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01204 XEOTIC Info		Gene Form	Protein
Classification	Investigative Agent
DME Modulation	MPC1304 inhibits the drug-metabolizing activity of DME CYP1A2				[105]
Pifithrin		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01431 XEOTIC Info		Gene Form	mRNA
Classification	Investigative Agent
DME Modulation	Pifithrin inhibits the expression of DME CYP1A2				[20]
Pyrazolanthrone		Click to Show/Hide the Detail			Induction
XEOTIC ID	XEO01445 XEOTIC Info		Gene Form	Protein
Classification	Investigative Agent
DME Modulation	Pyrazolanthrone induces the drug-metabolizing activity of DME CYP1A2				[157]
Rhein		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO01455 XEOTIC Info		Gene Form	Protein
Classification	Investigative Agent
DME Modulation	Rhein inhibits the drug-metabolizing activity of DME CYP1A2				[158]
Other Chemical Compound(s) or Element(s)
Chemical Compound		Click to Show/Hide the Full List of Xenobiotics: 2 Xenobiotics
Acridine		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00785 XEOTIC Info		Gene Form	Protein
Classification	Chemical Compound
DME Modulation	Acridine inhibits the drug-metabolizing activity of DME CYP1A2				[159]
Naphthalene		Click to Show/Hide the Detail			Inhibition
XEOTIC ID	XEO00764 XEOTIC Info		Gene Form	Protein
Classification	Chemical Compound
DME Modulation	Naphthalene inhibits the drug-metabolizing activity of DME CYP1A2 (IC50 = 700 microM)				[7]

References
1	The inducibility of human cytochrome P450 1A by environmental-relevant xenobiotics in the human hepatoma derived cell line HepG2. Environ Toxicol Pharmacol. 2009 Nov;28(3):370-8.
2	Adverse outcome pathway-driven analysis of liver steatosis in vitro: a case study with cyproconazole. Chem Res Toxicol. 2018 Aug 20;31(8):784-798.
3	Heme-oxygenase 1 gene expression is a marker for hexavalent chromium-induced stress and toxicity in human dermal fibroblasts. Toxicol Sci. 2008 Jun;103(2):325-34.
4	Characterization of human cytochrome P450 induction by pesticides. Toxicology. 2012 Mar 29;294(1):17-26.
5	Activation of protein kinase G Increases the expression of p21CIP1, p27KIP1, and histidine triad protein 1 through Sp1. Cancer Res. 2008 Jul 1;68(13):5355-62.
6	Organophosphorus pesticides enhance the genotoxicity of benzo(a)pyrene by modulating its metabolism. Mutat Res. 2009 Dec 1;671(1-2):84-92.
7	Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
8	Molecular mechanisms of discrotophos-induced toxicity in HepG2 cells: The role of CSA in oxidative stress. Food Chem Toxicol. 2017 May;103:253-260.
9	An evaluation of the cytochrome P450 inhibition potential of selected pesticides in human hepatic microsomes. J Environ Sci Health B. 2009 Aug;44(6):553-63.
10	The inhibition of major human hepatic cytochrome P450 enzymes by 18 pesticides: comparison of the N-in-one and single substrate approaches. Toxicol In Vitro. 2013 Aug;27(5):1584-8.
11	Inhibition of the human liver microsomal and human cytochrome P450 1A2 and 3A4 metabolism of estradiol by deployment-related and other chemicals. Drug Metab Dispos. 2006 Sep;34(9):1606-14.
12	Impact of isomalathion on malathion cytotoxicity and genotoxicity in human HepaRG cells. Chem Biol Interact. 2014 Feb 25;209:68-76.
13	Whole genome expression analysis in primary bronchial epithelial cells after exposure to sulphur mustard. Toxicol Lett. 2014 Nov 4;230(3):393-401.
14	Differential expression of pro-inflammatory and oxidative stress mediators induced by nitrogen dioxide and ozone in primary human bronchial epithelial cells. Inhal Toxicol. 2016 Jul;28(8):374-82.
15	Roles of nitric oxide in inflammatory downregulation of human cytochromes P450. Free Radic Biol Med. 2008 Mar 15;44(6):1161-8.
16	Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
17	In vitro toxicity of naphthalene, 1-naphthol, 2-naphthol and 1,4-naphthoquinone on human CFU-GM from female and male cord blood donors. Toxicol In Vitro. 2008 Sep;22(6):1555-61.
18	Ethanol potentiates the genotoxicity of the food-derived mammary carcinogen PhIP in human estrogen receptor-positive mammary cells: mechanistic support for lifestyle factors (cooked red meat and ethanol) associated with mammary cancer. Arch Toxicol. 2018 Apr;92(4):1639-1655.
19	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
20	A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
21	Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. J Allergy Clin Immunol. 2014 Aug;134(2):362-72.
22	Patients with atopic dermatitis have attenuated and distinct contact hypersensitivity responses to common allergens in skin. J Allergy Clin Immunol. 2015 Mar;135(3):712-20.
23	Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells. Drug Metab Dispos. 2004 Dec;32(12):1392-401.
24	Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumor agent 2-(4-amino-3-methylphenyl) benzothiazole. Mol Pharmacol. 2002 Jan;61(1):13-9.
25	Genotoxic effects of the cyanobacterial hepatotoxin cylindrospermopsin in the HepG2 cell line. Arch Toxicol. 2011 Dec;85(12):1617-26.
26	Modulation of aflatoxin B1-mediated genotoxicity in primary cultures of human hepatocytes by diindolylmethane, curcumin, and xanthohumols. Toxicol Sci. 2009 Dec;112(2):303-10.
27	Aryl hydrocarbon receptor activation and CYP1A induction by cooked food-derived carcinogenic heterocyclic amines in human HepG2 cell lines. Food Chem Toxicol. 2016 Nov;97:256-264.
28	Induction of CYP1A1, CYP1A2, and CYP1B1 mRNAs by nitropolycyclic aromatic hydrocarbons in various human tissue-derived cells: chemical-, cytochrome P450 isoform-, and cell-specific differences. Arch Toxicol. 2002 Jun;76(5-6):287-98.
29	Effect of metals on polycyclic aromatic hydrocarbon induction of CYP1A1 and CYP1A2 in human hepatocyte cultures. Toxicol Appl Pharmacol. 2001 Jan 15;170(2):93-103.
30	Modulation of aromatase activity and mRNA by various selected pesticides in the human choriocarcinoma JEG-3 cell line. Toxicology. 2006 Nov 10;228(1):98-108.
31	The activities of several detoxication enzymes are differentially induced by juices of garden cress, water cress and mustard in human HepG2 cells. Chem Biol Interact. 2004 Dec 7;150(3):211-9.
32	Platycodi Radix attenuates dimethylnitrosamine-induced liver fibrosis in rats by inducing Nrf2-mediated antioxidant enzymes. Food Chem Toxicol. 2013 Jun;56:231-9.
33	Aflatoxin B1 induces persistent epigenomic effects in primary human hepatocytes associated with hepatocellular carcinoma. Toxicology. 2016 Mar 28;350-352:31-9.
34	Hydroxystilbenes and methoxystilbenes activate human aryl hydrocarbon receptor and induce CYP1A genes in human hepatoma cells and human hepatocytes. Food Chem Toxicol. 2017 May;103:122-132.
35	Activity profiles of 309 ToxCast?chemicals evaluated across 292 biochemical targets. Toxicology. 2011 Mar 28;282(1-2):1-15.
36	Gnetin H isolated from Paeonia anomala inhibits FcRI-mediated mast cell signaling and degranulation. J Ethnopharmacol. 2014 Jul 3;154(3):798-806.
37	Mono-methylindoles induce CYP1A genes and inhibit CYP1A1 enzyme activity in human hepatocytes and HepaRG cells. Toxicol Lett. 2019 Oct 1;313:66-76.
38	The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006 Nov 25;79(26):2432-40.
39	Regulation of cutaneous drug-metabolizing enzymes and cytoprotective gene expression by topical drugs in human skin in vivo. Br J Dermatol. 2006 Aug;155(2):275-81.
40	Interaction of modified cyclodextrins with cytochrome P-450. Biosci Biotechnol Biochem. 2005 Jan;69(1):246-8.
41	Asian dust storm particles induce a broad toxicological transcriptional program in human epidermal keratinocytes. Toxicol Lett. 2011 Jan 15;200(1-2):92-9.
42	Tissue transglutaminase serves as an inhibitor of apoptosis by cross-linking caspase 3 in thapsigargin-treated cells. Mol Cell Biol. 2006 Jan;26(2):569-79.
43	Inhibition of human CYP1A2 activity in vitro by methylxanthines: potent competitive inhibition by 8-phenyltheophylline. Xenobiotica. 2001 Mar;31(3):135-51.
44	Induction of cytochromes P450 1A1 and 1A2 by tanshinones in human HepG2 hepatoma cell line. Toxicol Appl Pharmacol. 2011 Apr 1;252(1):18-27.
45	Pyranoflavones: a group of small-molecule probes for exploring the active site cavities of cytochrome P450 enzymes 1A1, 1A2, and 1B1. J Med Chem. 2013 May 23;56(10):4082-92.
46	Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
47	Analysis of glycogen synthase kinase inhibitors that regulate cytochrome P450 expression in primary human hepatocytes by activation of beta-catenin, aryl hydrocarbon receptor and pregnane X receptor signaling. Toxicol Sci. 2015 Nov;148(1):261-75.
48	Isoform-selective inhibition of chrysin towards human cytochrome P450 1A2Kinetics analysis, molecular docking, and molecular dynamics simulations. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6008-12.
49	Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem. 2007 Aug 1;15(15):5047-60.
50	Inhibition of human cytochrome P450 1B1, 1A1 and 1A2 by antigenotoxic compounds, purpurin and alizarin. Mutat Res. 2002 Oct 31;508(1-2):147-56.
51	Protopine and allocryptopine increase mRNA levels of cytochromes P450 1A in human hepatocytes and HepG2 cells independently of AhR. Toxicol Lett. 2011 Jun 10;203(2):135-41.
52	The natural anthraquinones from Rheum palmatum induced the metabolic disorder of melatonin by inhibiting human CYP and SULT enzymes. Toxicol Lett. 2016 Nov 16;262:27-38.
53	Design and synthesis of new alpha-naphthoflavones as cytochrome P450 (CYP) 1B1 inhibitors to overcome docetaxel-resistance associated with CYP1B1 overexpression. J Med Chem. 2015 Apr 23;58(8):3534-47.
54	Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans. Eur J Clin Pharmacol. 2005 Nov;61(10):755-61.
55	Structure-function relationships of inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives. Chem Res Toxicol. 2010 Dec 20;23(12):1921-35.
56	Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
57	Metabolism of polybrominated diphenyl ethers (PBDEs) by human hepatocytes in vitro. Environ Health Perspect. 2009 Feb;117(2):197-202.
58	In vivo prediction of CYP-mediated metabolic interaction potential of formononetin and biochanin A using in vitro human and rat CYP450 inhibition data. Toxicol Lett. 2015 Nov 19;239(1):1-8.
59	Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
60	Interactions of sesquiterpenes zederone and germacrone with the human cytochrome P450 system. Toxicol In Vitro. 2013 Sep;27(6):2005-12.
61	Phytochemical-induced changes in gene expression of carcinogen-metabolizing enzymes in cultured human primary hepatocytes. Xenobiotica. 2004 Jul;34(7):619-32.
62	The role S-nitrosylation in manganese-induced autophagy dysregulation in SH-SY5Y cells. Environ Toxicol. 2017 Dec;32(12):2428-2439.
63	Apoptosis of human gastric cancer SGC-7901 cells induced by mitomycin combined with sulindac. World J Gastroenterol. 2005 Mar 28;11(12):1829-32.
64	Towards a systematic analysis of human short-chain dehydrogenases/reductases (SDR): Ligand identification and structure-activity relationships. Chem Biol Interact. 2015 Jun 5;234:114-25.
65	Renal toxicity through AhR, PXR, and Nrf2 signaling pathway activation of ochratoxin A-induced oxidative stress in kidney cells. Food Chem Toxicol. 2018 Dec;122:59-68.
66	Responsiveness assessment of a 3D tetra-culture alveolar model exposed to diesel exhaust particulate matter. Toxicol In Vitro. 2018 Dec;53:67-79.
67	One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol Res. 2013 Jun;72:69-82.
68	Coordinate up-regulation of TMEM97 and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of ovarian cancer. BMC Cancer. 2007 Dec 11;7:223.
69	Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem. 2002 Jan 3;45(1):160-4.
70	Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
71	Effect of structural modification on the inhibitory selectivity of rutaecarpine derivatives on human CYP1A1, CYP1A2, and CYP1B1. Bioorg Med Chem Lett. 2003 Aug 4;13(15):2535-8.
72	Inhibition of human cytochrome P450 enzymes by the natural hepatotoxin safrole. Food Chem Toxicol. 2005 May;43(5):707-12.
73	Supplementation of healthy volunteers with nutritionally relevant amounts of selenium increases the expression of lymphocyte protein biosynthesis genes. Am J Clin Nutr. 2008 Jan;87(1):181-9.
74	Transcriptomic responses of cancerous and noncancerous human colon cells to sulforaphane and selenium. Chem Res Toxicol. 2014 Mar 17;27(3):377-86.
75	Regulation of human carbonyl reductase 3 (CBR3; SDR21C2) expression by Nrf2 in cultured cancer cells. Biochemistry. 2010 Oct 5;49(39):8499-511.
76	Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract. Biochem Biophys Res Commun. 2004 Jun 11;318(4):1072-8.
77	Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95.
78	Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
79	QT interval prolongation and Torsades de Pointes in a patient receiving zolpidem and amiodarone. Cardiology. 2006;105(3):146-7.
80	Effects of histone deacetylation and DNA methylation on the constitutive and TCDD-inducible expressions of the human CYP1 family in MCF-7 and HeLa cells. Toxicol Lett. 2003 Sep 30;144(2):247-56.
81	An in vitro approach to assessing a potential drug interaction between MDMA (ecstasy) and caffeine. Toxicol In Vitro. 2014 Mar;28(2):231-9.
82	Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
83	Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther. 2006 Nov;80(5):440-456.
84	In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
85	Size-dependent effects of nanoparticles on the activity of cytochrome P450 isoenzymes. Toxicol Appl Pharmacol. 2010 Feb 1;242(3):326-32.
86	Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
87	Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. Pharmacogenomics J. 2009 Jun;9(3):208-17.
88	In vitro analysis of factors influencing CYP1A2 expression as potential determinants of interindividual variation. Pharmacol Res Perspect. 2017 Mar 2;5(2):e00299.
89	Dehydroepiandrosterone post-transcriptionally modifies CYP1A2 induction involving androgen receptor. Chem Biol Interact. 2013 May 25;203(3):597-603.
90	Dexamethasone controls aryl hydrocarbon receptor (AhR)-mediated CYP1A1 and CYP1A2 expression and activity in primary cultures of human hepatocytes. Chem Biol Interact. 2009 May 15;179(2-3):288-96.
91	A chemoproteomic platform to assess bioactivation potential of drugs. Chem Res Toxicol. 2017 Oct 16;30(10):1797-1803.
92	Differences in apoptotic signaling and toxicity between dimethylmonothioarsinic acid (DMMTAV) and its active metabolite, dimethylarsinous acid (DMAIII), in HepaRG cells: possibility of apoptosis cascade based on diversity of active metabolites of DMMTAV. J Trace Elem Med Biol. 2018 Dec;50:188-197.
93	Interaction study between enoxacin and fluvoxamine. Ther Drug Monit. 2005 Jun;27(3):349-53.
94	Inhibition of cytochrome P450 by ethambutol in human liver microsomes. Toxicol Lett. 2014 Aug 17;229(1):33-40.
95	Optical isomers of dihydropyridine calcium channel blockers display enantiospecific effects on the expression and enzyme activities of human xenobiotics-metabolizing cytochromes P450. Toxicol Lett. 2016 Nov 16;262:173-186.
96	Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
97	Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity. Drug Metab Dispos. 2012 May;40(5):943-51.
98	Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J Pharmacol Exp Ther. 1994 Apr;269(1):384-92.
99	An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes. Chem Biol Interact. 1998 Jul 3;114(1-2):1-13.
100	Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
101	Lycopene: an antioxidant and radioprotector against gamma-radiation-induced cellular damages in cultured human lymphocytes. Toxicology. 2009 Jul 28;262(1):43-9.
102	Meclofenamate sodium is an inhibitor of both the 5-lipoxygenase and cyclooxygenase pathways of the arachidonic acid cascade in vitro. Prostaglandins Leukot Med. 1986 Aug;23(2-3):229-38.
103	Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica. 1996 Jul;26(7):681-93.
104	Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors. Drug Metab Dispos. 2013 Jan;41(1):60-71.
105	Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
106	Persistence of epigenomic effects after recovery from repeated treatment with two nephrocarcinogens. Front Genet. 2018 Dec 3;9:558.
107	Multiplicity of nuclear receptor activation by PFOA and PFOS in primary human and rodent hepatocytes. Toxicology. 2011 Oct 9;288(1-3):8-17.
108	High perfluorooctanoic acid exposure induces autophagy blockage and disturbs intracellular vesicle fusion in the liver. Arch Toxicol. 2017 Jan;91(1):247-258.
109	Gene expression changes in human lung cells exposed to arsenic, chromium, nickel or vanadium indicate the first steps in cancer. Metallomics. 2012 Aug;4(8):784-93.
110	Curcumin is a tight-binding inhibitor of the most efficient human daunorubicin reductase--Carbonyl reductase 1. Chem Biol Interact. 2015 Jun 5;234:162-8.
111	Activity of NADPH-cytochrome P-450 reductase of the human heart, liver and lungs in the presence of (-)-epigallocatechin gallate, quercetin and resveratrol: an in vitro study. Basic Clin Pharmacol Toxicol. 2005 Aug;97(2):74-9.
112	Resveratrol in human hepatoma HepG2 cells: metabolism and inducibility of detoxifying enzymes. Drug Metab Dispos. 2007 May;35(5):699-703.
113	Effects of endocrine disruptors on genes associated with 17beta-estradiol metabolism and excretion. Steroids. 2008 Nov;73(12):1242-51.
114	Ascorbic acid partly antagonizes resveratrol mediated heme oxygenase-1 but not paraoxonase-1 induction in cultured hepatocytes - role of the redox-regulated transcription factor Nrf2. BMC Complement Altern Med. 2011 Jan 3;11:1.
115	A comprehensive evaluation of anti-diabetic drugs on nuclear receptor PXR platform. Toxicol In Vitro. 2019 Oct;60:347-358.
116	TSU-16, (Z)-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone, is a potent activator of aryl hydrocarbon receptor and increases CYP1A1 and CYP1A2 expression in human hepatocytes. Chem Biol Interact. 2010 Apr 15;185(1):33-41.
117	High fat diet-induced hepatic 18-carbon fatty acids accumulation up-regulates CYP2A5/CYP2A6 via NF-E2-related factor 2. Front Pharmacol. 2017 May 15;8:233.
118	Sulforaphane-induced apoptosis in human leukemia HL-60 cells through extrinsic and intrinsic signal pathways and altering associated genes expression assayed by cDNA microarray. Environ Toxicol. 2017 Jan;32(1):311-328.
119	Comparison of cellular and transcriptomic effects between electronic cigarette vapor and cigarette smoke in human bronchial epithelial cells. Toxicol In Vitro. 2017 Dec;45(Pt 3):417-425.
120	Long-term exposure to cigarette smoke extract induces hypomethylation at the RUNX3 and IGF2-H19 loci in immortalized human urothelial cells. PLoS One. 2013 May 28;8(5):e65513.
121	From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
122	Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab. 2005 Oct;6(5):413-54.
123	Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid. Cancer Chemother Pharmacol. 2008 Apr;61(5):791-802.
124	Inhibitors of cytochrome P450 (CYP) 1B1. Eur J Med Chem. 2017 Jul 28;135:296-306.
125	The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
126	Selenite-mediated production of superoxide radical anions in A549 cancer cells is accompanied by a selective increase in SOD1 concentration, enhanced apoptosis and Se-Cu bonding. J Biol Inorg Chem. 2014 Aug;19(6):813-28.
127	Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Arch Biochem Biophys. 2003 Jan 1;409(1):32-44.
128	Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells. Int J Cancer. 2008 Mar 1;122(5):990-8.
129	Antioxidant and antigenotoxic effects of plant cell wall hydroxycinnamic acids in cultured HT-29 cells. Mol Nutr Food Res. 2005 Jun;49(6):585-93.
130	Enzyme induction and cytotoxicity in human hepatocytes by chlorpyrifos and N,N-diethyl-m-toluamide (DEET). Drug Metabol Drug Interact. 2008;23(3-4):237-60.
131	Impact of environmental chemicals on the transcriptome of primary human hepatocytes: potential for health effects. J Biochem Mol Toxicol. 2016 Aug;30(8):375-95.
132	Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther. 2001 Dec;299(3):874-82.
133	Trans-resveratrol, but not other natural stilbenes occurring in food, carries the risk of drug-food interaction via inhibition of cytochrome P450 enzymes or interaction with xenosensor receptors. Toxicol Lett. 2019 Jan;300:81-91.
134	Butyrate interacts with benzo[a]pyrene to alter expression and activities of xenobiotic metabolizing enzymes involved in metabolism of carcinogens within colon epithelial cell models. Toxicology. 2019 Jan 15;412:1-11.
135	Effects of Andrographis paniculata extract and Andrographolide on hepatic cytochrome P450 mRNA expression and monooxygenase activities after in vivo administration to rats and in vitro in rat and human hepatocyte cultures. Chem Biol Interact. 2009 May 15;179(2-3):247-55.
136	Differential toxicity of heterocyclic aromatic amines and their mixture in metabolically competent HepaRG cells. Toxicol Appl Pharmacol. 2010 Jun 1;245(2):256-63.
137	Steviol, an aglycone of steviol glycoside sweeteners, interacts with the pregnane X (PXR) and aryl hydrocarbon (AHR) receptors in detoxification regulation. Food Chem Toxicol. 2017 Nov;109(Pt 1):130-142.
138	Comparative biological impacts of an aerosol from carbon-heated tobacco and smoke from cigarettes on human respiratory epithelial cultures: a systems toxicology assessment. Food Chem Toxicol. 2018 May;115:109-126.
139	Differential inhibition of human cytochrome P450 enzymes by epsilon-viniferin, the dimer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beverages. Life Sci. 2003 Jul 18;73(9):1199-213.
140	Inhibition of human cytochrome P450 enzymes by licochalcone A, a naturally occurring constituent of licorice. Toxicol In Vitro. 2015 Oct;29(7):1569-76.
141	Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5.
142	Triazine herbicides inhibit relaxin signaling and disrupt nitric oxide homeostasis. Toxicol Appl Pharmacol. 2016 Sep 15;307:10-18.
143	Neoplastic-like transformation effect of single-walled and multi-walled carbon nanotubes compared to asbestos on human lung small airway epithelial cells. Nanotoxicology. 2014 Aug;8(5):485-507.
144	Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
145	Phase II enzymes induction blocks the enhanced IgE production in B cells by diesel exhaust particles. J Immunol. 2006 Sep 1;177(5):3477-83.
146	In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole. Drug Metab Pharmacokinet. 2003;18(5):287-95.
147	Baicalin protects mice from aristolochic acid I-induced kidney injury by induction of CYP1A through the aromatic hydrocarbon receptor. Int J Mol Sci. 2015 Jul 20;16(7):16454-68.
148	Inhibition of human hepatic CYP isoforms by mGluR5 antagonists. Life Sci. 2004 Jul 9;75(8):947-53.
149	Sulfur mustard downregulates iNOS expression to inhibit wound healing in a human keratinocyte model. J Dermatol Sci. 2008 Mar;49(3):207-16.
150	Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
151	Characterization of activating signal cointegrator-2 as a novel transcriptional coactivator of the xenobiotic nuclear receptor constitutive androstane receptor. Mol Endocrinol. 2005 Jul;19(7):1711-9.
152	Liver X receptor alpha bidirectionally transactivates human CYP1A1 and CYP1A2 through two cis-elements common to both genes. Toxicol Lett. 2012 Nov 23;215(1):16-24.
153	Effects of avasimibe on cytochrome P450 2C9 expression in vitro and in vivo. Drug Metab Dispos. 2004 Dec;32(12):1370-6.
154	In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions. Drug Metab Dispos. 2005 Nov;33(11):1628-36.
155	Inhibition of carcinogen-bioactivating cytochrome P450 1 isoforms by amiloride derivatives. Biochem Pharmacol. 2004 May 1;67(9):1711-9.
156	Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM). Eur J Med Chem. 2015 Oct 20;103:210-22.
157	Glutathione-dependent cytotoxicity of the chloroacetanilide herbicides alachlor, metolachlor, and propachlor in rat and human hepatoma-derived cultured cells. Cell Biol Toxicol. 1999;15(5):325-32.
158	Functional expression and comparative characterization of nine murine cytochromes P450 by fluorescent inhibition screening. Drug Metab Dispos. 2008 Jul;36(7):1322-31.
159	Inhibition of human CYP1A2 oxidation of 5,6-dimethyl-xanthenone-4-acetic acid by acridines: a molecular modelling study. Clin Exp Pharmacol Physiol. 2005 Aug;32(8):633-9.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.